Radionuclide Therapy by Stephen M. Karesh, Ph.D. Nuclear Medicine Department Loyola University Medical Center.

Slides:



Advertisements
Similar presentations
Frank P. Dawry Thyroid Cancer Therapy Radioactive Iodine (I-131)
Advertisements

32 P Module Objectives  To understand the physical nature of 32 P.  To understand the 32 P is both and internal and external radiation hazard.  To understand.
Radioisotopes & Radiopharmaceuticals
8 Radionuclide therapy. The therapeutic use of radiopharmaceuticals is based on the concept of selective localization of radiopharmaceuticals coupled.
Alexander Brandl ERHS 630 Radiation and Tissue Weighting Factors Environmental and Radiological Health Sciences.
O Level Physics Chapter :25: Use of Radioactivity
Radiation Protection in Radiotherapy
Radio activity is important in medicine because it is used in diagnosing and therapy. Therapy is treatment such as treating cancer. Tumours are destroyed.
Radioiodine Therapy for Graves’ Disease Dr. Khalid B. Makhdomi Nuclear Medicine Physician Aga Khan University Hospital, Nairobi.
“Liquid Brachytherapy” Direct Administration of Therapeutic Radioisotopes Into Tumors Jim Simon,* 1 Stan Stearns, 2 Kenneth McMillan, 1 Max Loy, 2 and.
Radiology is concerned with the application of radiation to the human body for diagnostically and therapeutically purposes. This requires an understanding.
Radioisotopes in Medicine
4.1 Natural Radioactivity
RADIATION SAFETY Phil Facey Lead Superintendent Radiographer
Radioactivity The Professional Development Service for Teachers is funded by the Department of Education and Science under the National Development Plan.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Introduction to Brachytherapy
Radiotherapy for Kidney cancer
3 Uses of Medical Radiation Jenifer McConnell. Medical Uses of Radiation My project is on three medical uses of Radiation --- 1)X-rays, diagnostic. 2)Radiation.
Gemma Downey. Radiation Therapy Also called radiation oncology, radiation therapy is the use of ionizng radiation as part of cancer treatment to control.
Introduction to Nuclear Medicine
Nuclear Medicine Olivia Nicholson Sannhi Pham Alex Bynum Ryan Hadfeild Olivia Nicholson.
Internal Emitters Radioactive material within the body.
Section 3 Nuclear Changes Section 3: Nuclear Radiation Today Preview Key Ideas Bellringer Where is Radiation? Beneficial Uses of Nuclear Radiation Risks.
Radiation Safety in Human Research Studies Mack L. Richard, MS, CHP IUPUI/IUMC Radiation Safety Office.
IB Objectives - Radiation in Medicine
The Nucleus and Radioactivity
Nuclear Chemistry A BRIEF Overview. Just the Basics Nuclear chemistry is not a huge focus, but you should be aware of the basics Nuclear chemistry is.
Section 3 Nuclear Changes Where is Radiation? 〉 We are continually exposed to radiation from natural sources, such as the sun, soil, rocks, and plants.
9 Radionuclide therapy.
Radiophamaceuticals in Nuclear Cardiac Imaging Vasken Dilsizian, M.D. Professor of Medicine and Radiology Director of Cardiovascular Nuclear Medicine and.
Prepared By : Miss. Sana’a AL-Sulami Teacher Assistant.
VIII.3. Optimization of Protection for Medical Exposures in Nuclear Medicine 2. Dose to patient Postgraduate Educational Course in Radiation Protection.
Based on the number of protons and neutrons, an atom can be stable or unstable. Generally, small atoms require an equal number of p & n for stability,
Internal Radiation Dosimetry Lab 9. Radiation Measurement We use different terms depending on whether: 1.The radiation is coming from a radioactive source.
Using Radiation in Medicine. There are 3 main uses of radiation in medicine: Treatment Diagnosis Sterilization.
CP Biology Chapter 2 The Chemistry of Life. Chemicals make up ALL matter – living and nonliving. All life processes are chemical reactions. Chemical signals.
Power of science implemented in life quality Improvement of the effectiveness of radiation therapy with radiomodification by Polyplatillen and Fluoropyrimidine.
Training Module 3 – Version 1.1 For Internal Use Only ® Radiation Therapy 
RADIATION SAFETY Mrs. Brinston. Introduction As a healthcare worker, you know that radiation is an important tool for detecting and treating diseases.
 Radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases. They may be given to the patient in several different.
Section 1Nuclear Changes Section 1: What is Radioactivity?
Verluma Nofetumomab Merpentan (Fragment). Indications For the detection and staging of previously untreated small cell lung cancer. It must be confirmed.
1 Chapter 9 Nuclear Radiation 9.1 Natural Radioactivity Copyright © 2009 by Pearson Education, Inc.
VIII.0 Medical Exposures in Nuclear Medicine.
Brachytherapy and GYN malignancy
Application of Nuclear Chemistry Cancer Treatment – Cancer cells are more susceptible to radiation bc they are fast growing. Thyroid cancer can be treated.
By Rini Agustin.  Introduction  Radioctive and How radioactive is produced : atom, radioactivity and radioactive decay  Radiopharmaceutical preparation.
Nuclear Chemistry: The Heart of Matter. 2 Radioisotopes Radioactive decay Radioactive decay – Many isotopes are unstable – Many isotopes are unstable.
Nuclear Medicine Technique I 355 RAD L.Aya Ahmed Saeed.
MEDICAL USES FOR RADIATION Andres Perez P.1 Level 4 MT10.
Introduction to NM Omima Adam NMT 231. What is nuclear medicine NM Is the branch of medicine that uses radiation and nuclear properties of radionuclide's.
Nuclear medicine Essential idea Nuclear radiation, whilst dangerous owing to its ability to damage cells and cause mutations, can also be used to both.
Iodine 131 Medical Uses.
ESTIMATION OF HOSPITAL STAY TIME FOR CA-THYROID PATIENTS TREATED WITH RADIOIODINE-131 By Sudipta Saha 1 Dr. Ashoke kumar paul 2 Dr. M. Shakilur rahman.
3 rd year Inorganic Pharmaceutical Chemistry College of Pharmacy.

5.5 Medical Applications Using Radioactivity
Nuclear medicine Essential idea
The environmental dose measurements of high dose Iodine-131 treated thyroid cancer patients during hospitalization period Nina TUNÇEL  Department of Physics,
Campos M et al. Proc EHA 2013;Abstract B2009.
Campos M et al. Proc EHA 2013;Abstract B2009.
Radiation related Procedures and in-Utero Effects
Nuclear Radiology Thyroid
Radio Iodine Therapy In Cancer Thyroid
Maria Belgun, L.Dumitriu, A.Goldstein, Mariana Purice, F.Alexiu
Radiation in Medicine.
Nofetumomab Merpentan (Fragment)
Radioisotopes in Medicine
Nuclear medicine Essential idea
Presentation transcript:

Radionuclide Therapy by Stephen M. Karesh, Ph.D. Nuclear Medicine Department Loyola University Medical Center

Types of Therapy Performed in Hospitals Radiopharmaceutical Therapy Brachytherapy Teletherapy

Therapeutic Radiopharmaceutical a radioactive drug which, when used for therapeutic purposes, typically elicits no physiological response from the patient.

Characteristics of the Ideal Therapeutic Radiopharmaceutical 1. Moderately long t eff (measured in days). For 131 I NaI, t eff in thyroid = 6 d 2. Prefer  particle emitters (high LET) to maximize tissue dose/mCi injected. 3. Prefer high energy (>1 MeV) 4. Must have high target:non-target ratio to minimize radiation dose to non-target organs 5. Prefer rapid excretion of unbound material. 6. Readily available, inexpensive 7. Minimal radiation exposure to personnel in contact with patient, i.e., 32 P

Radionuclide Therapy Types of Emissions Used for Therapy alpha particles beta- particles electrons gamma rays X-rays

Radionuclide Therapy Radioisotopes Used for Therapy I-131 for treatment of thyroid diseases P-32 for treatment of polycythemia vera P-32, Sr-89, Sm-153, Re-186 for palliation of pain from bony metastases Dy-165, Ho-166 for radiation synovectomy

Group IV Radiopharmaceuticals Includes all prepared therapeutic radiopharmaceuticals whose use does not require hospitalization for purposes of radiation safety.

Examples of Group IV Radiopharmaceuticals I NaI for treatment of hyperthyroidism P as soluble sodium phosphate for treatment of polycythemia vera P as insoluble chromic phosphate colloid for intracavitary treatment of malignant effusions Sr as soluble SrCl 2 for palliation of pain in patients with metastatic breast or prostate cancer. 5. Any investigational therapeutic radiopharmaceutical not requiring hospitalization for purposes of radiation safety.

Group V Radiopharmaceuticals Includes all therapeutic radiopharmaceuticals that require hospitalization for purposes of radiation safety.

Examples of Group V Radiopharmaceuticals I NaI for treatment of thyroid Ca Au for intracavitary treatment of malignant effusions 3. Any investigational therapeutic radiopharmaceutical requiring hospitalization for purposes of radiation safety.

Group VI Radiopharmaceuticals Includes sources and devices containing byproduct material that are used for therapeutic applications.

Examples of Group VI Radiopharmaceuticals Am as a sealed source in a bone mineral analyzer Cs encased in needles and applicator cells for topical, interstitial, and intracavitary treatment of cancer Co encased in needles and applicator cells for topical, interstitial, and intracavitary treatment of cancer Au seeds for interstitial treatment of Ca

Group VI Radiopharmaceuticals I as a sealed source in a bone mineral analyzer Ir as seeds encased in nylon ribbon for interstitial treatment of cancer Sr sealed in an applicator for treatment of superficial eye conditions I as seeds for interstitial treatment of cancer

Thyroid Diseases Treatable with 131 I-NaI - hyperthyroidism (Graves disease) - toxic nodular goiter (Plummer’s disease) - thyroid carcinoma (ranked in order of likelihood of 131 I uptake) 1. Follicular 2. Papillary the other two types of thyroid cancer, medullary and anaplastic, are not treatable with I-131

Decay Scheme of I I Stable Xe 54 11  10  9  6  4  2  14  13  12  11  8  7  5  3  1  2  3  4   5  6

Quiz This decay scheme indicates that there are 14 gammas and 6 betas emitted from I-131. Therefore, True or False, 14/20 of the tissue damage is attributable to gammas and 6/20 to betas.

Answer False for 2 reasons: 1. The LET (Linear Transfer Rate) for betas is much higher than for gammas; consequently they confer a much higher radiation dose 2. The fractions 14/20 and 6/20 imply that the % abundance of each of these 20 emissions is exactly 5%, which is not possible. In fact the % abundances vary from a fraction of 1% to almost 85%. Correct answer is that ~90% of tissue damage is attributable to beta particles.

Typical Doses of 131 I Compounds route of procedure dose (mCi) administration raiu, normal oral raiu & scan, substernal oral total body mets survey 5-10 oral hyperthyroidism 5-15 oral toxic nodular goiter 25 oral thyroid Ca therapy oral

Radiation Dosimetry of 131 I- NaI following oral administration of 10 mCi dose of 131 I-NaI for treatment of hyperthyroidism, 90% of dose to tissue is achieved by  - emissions. For a hyperthyroid patient treated with I-131: absorbed radiation dose Tissue (rads/10 mCi of I-131) Thyroid 11,000. Testes 9.2 Ovaries 9.3 Whole body16.0

Dose Determination for Therapy in Graves Disease Method 1 Measure % uptake; estimate mass of thyroid (g) Dose =  Ci/g x mass (g) x 100% % uptake disadvantage: since  Ci /g is a wide range, it is difficult to determine the appropriate factor for an individual patient. Use of this formula often results in incorrect estimate of the required dose, resulting in over- or under-dosing of patient.

Dose Determination for Therapy in Graves Disease Method 2 A standard dose of 131 I NaI is given orally to all patients (8 mCi to females, 10 mCi to males) Advantage: adequately treats 85% of all Graves disease patients with 1 treatment. Disadvantage: of the 15% who are refractory, 10% require a second administration of 131 I; the other 5% require a third dose of 131 I.

Response of hyperthyroid patients to treatment with 131 I sodium iodide day of administration no immediate effect 4-6 weekspatient begins to notice beneficial effects 12 weeksmaximum beneficial effects observed 6 months few observable changes after this interval

Long-term Side Effect As indicated in the following graph, the rate of hypothyroidism after the first year is 3%/year for all patients treated with 131 I sodium iodide for Graves disease. They are treated with synthroid daily for the rest of their lives.

Rate of Induction of Hypothyroidism Following Therapy with 131 I-NaI % hypothyroid years post therapy with 131 I-NaI

1. Keep your distance to minimize personal radiation dose 2. Patient is assigned a private room 3. Everyone involved with patient must wear film badge 4. Gloves must be used by patient to handle telephone, bed controls Precautions to be Observed with High-dose I-131 Therapy Patient

5. Housekeeping not allowed in room until room is released by RSO 6. No visitors allowed for at least 24 hr 7. No bed baths 8. Patient must stay in bed unless instructed otherwise Precautions to be Observed with High-dose I-131 Therapy Patient

9. Absorbent pads taped to floor from toilet to bed 10. Patient must use disposable items for food service 11. Diagnostic blood samples taken by Nuclear Medicine

Precautions to be Observed with High-dose I-131 Therapy Patient 12. If patient dies, attending physician must be notified immediately 13. Room must be surveyed by RSO prior to release for next use. 14. Every participant in therapy must have thyroid counted 24 hr post dose

Patient Release Criteria Reading <5 mR/hr at 1 meter from patient’s chest, which is equivalent to a body burden <30 mCi of I-131.

89 Sr strontium chloride Therapy for Palliation of Bony Metastases

Physical Characteristics of 89 Sr prepared by 88 Sr(n,  ) 89 Sr t 1/2 = 50.5 days type of decay:  - maximum energy: MeV, 100% range of  - in tissue: 8 mm

Advances in Cancer Therapy Longer survival in many cancers Better pain control medication More aggressive radiotherapy End result: More people living with bone pain.

Bony Metastases in Breast and Prostate Cancer Prostate cancer 50% of patients have bone disease at time of diagnosis Breast cancer 15% of stage III patients and 50% of Stage IV patients have bone metastases

Therapeutic Approaches to Bone Pain NSAIDs Chemotherapy Hormonal Therapy External Beam Radiation Narcotic Therapy Radiopharmaceutical Therapy

Historical Approach to Radionuclide Therapy Na 3 32 PO 4 in 1940’s 89 SrCl 2 in late 1980’s 153 Sm EDTMP in late 1990’s

32 P-Na 3 PO 4 1. long history % response rate in literature 3. significant marrow depression- end point is toxicity 4. infrequently used

89 Sr strontium chloride therapy for palliation of bony metastases 1. Indications: bone pain caused by any primary malignancy metastatic to bone. Implication: Must have a bone scan positive for metastases. Most commonly used for breast and prostate cancer 2. Palliative, not curative 3. Bone localizer; calcium analog with distribution very similar to 99m Tc-MDP

89 Sr Strontium Chloride Therapy for Palliation of Bony Metastases 4. 80% Response rate overall 5. Ratio of metastatic lesions to normal bone = 5:1 6. Ratio of metastatic lesions to marrow = 10:1 7. Retention of 89 Sr in metastases longer than in bone

89 Sr Strontium Chloride Therapy for Palliation of Bony Metastases 8. No reported adverse reactions % of patients have measurable decrease in WBC and platelets 10. Recovery begins at about 6 weeks 11. Flare phenomenon often prognostic indicator of successful treatment

Typical Dose: 89 Sr chloride 4 mCi given by IV Injection for intractable bone pain from prostate, breast cancer or other primary malignancy

Radiation dosimetry of 89 Sr chloride organ rad/mCi red marrow 80.0 bladder wall 0.5 whole body 6.0

89 SrCl 2 Therapy: Clinical Outcomes 80% response divided into 3 groups: moderate response morphine codeine marked response morphine advil dramatic response morphine no meds

Typical Administered Doses for 32 P Compounds polycythemia vera soluble 32 P Na 3 PO mCiIV injection malignant effusions colloidal 32 P CrPO mCi intracavitary injection

32 P Na phosphate for treatment of p. vera 1. IV injection of 3-4 mCi for initial treatment, which adequately treats 50% of patients. 2. Of 50% requiring 2nd injection, 35% are successfully treated. Remainder are refractory to treatment and may require 3rd or 4th dose. 3. Median survival time for untreated patients after time of diagnosis is 1.5 yr. After treatment with 32 P Na phosphate, interval is increased to 12 yr % incidence of leukemia in successfully treated patients.

32 P Na phosphate for treatment of polycythemia vera Controversy Is 11% incidence of leukemia a result of injection of 32 P Na phosphate or is P. Vera a preleukemogenic condition whose natural course is development of leukemia? The increased risk of leukemia is probably partially attributable to both causes.

Radiation dosimetry following IV injection of 4 mCi of 32 P Na phosphate. organabsorbed dose (rads) skeleton240 liver 24 spleen 29 gonads 4 whole body 40

32 P chromic phosphate colloid for palliation of malignant effusions 1. Intracavitary injection: 10 mCi in 250 ml saline 2. >90% of patients respond => significantly decreased frequency of "tapping" required to remove fluid. 3. Rarely need to retreat patient. 4. Palliative, not curative. 5. Approved drug, <$1000 per treatment